Cellectricon Launches Grant to Fund Electroporation-based Research
News Jul 10, 2013
As a provider of advanced cell-based screening technologies and services, Cellectricon is inviting researchers to apply for the recently launched Cellaxess Project Grant. The Grant is open to any scientist or research group wanting to capitalize on the advanced electromanipulation capabilities of the Cellaxess® platform for the cellular delivery of non-genetic material, particularly small molecules and peptides. Winners will be selected from two categories, basic and applied cell-based research, and will receive the Cellaxess ACE platform, along with all consumables and reagents, for a fully supported project. Interested groups should submit a research proposal by Wednesday 31st July, explaining how they intend to use the Cellaxess technology in their research project, using the application form available on Cellectricon’s website.
The Cellaxess electroporation system, which can be used for the in-situ transfection of any adherent cell-type, ensures minimal cell processing for perfectly retained cell function and morphology. As such, the platform is ideal for the delivery of non-genetic material, including antibodies, peptides and other small molecules, to challenging cells such as primary and IPS-derived neuronal cell types. Cellectricon welcomes proposals that exploit these unique capabilities of the Cellaxess system and, via the Cellaxess Project Grant, is keen to support and develop the proprietary work of research groups worldwide. Helping to expand the scope of such research, the Grant provides a unique opportunity for scientists to access cutting-edge technologies and gain first-hand advice from Cellectricon’s expert team.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE